{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:54:49Z","timestamp":1787540089321,"version":"build-2736575974"},"reference-count":251,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Mol Med"],"DOI":"10.3892\/ijmm.2019.4418","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T06:36:54Z","timestamp":1575441414000},"source":"Crossref","is-referenced-by-count":74,"title":["Precision medicine for human cancers with Notch signaling dysregulation (Review)"],"prefix":"10.3892","author":[{"given":"Masuko","family":"Katoh","sequence":"first","affiliation":[{"name":"M & M PrecMed, Tokyo 113\u20110033, National Cancer Center, Tokyo 104\u20110045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Omics Network, National Cancer Center, Tokyo 104\u20110045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"key20200713162310_b1-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrg3272","article-title":"The Notch signalling system: Recent insights into the complexity of a conserved pathway","volume":"13","author":"Guruharsha","year":"2012","journal-title":"Nat Rev Genet"},{"key":"key20200713162310_b2-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrm.2016.94","article-title":"Notch signalling in context","volume":"17","author":"Bray","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200713162310_b3-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2018.07.009","article-title":"Notch signaling in the tumor micro-environment","volume":"34","author":"Meurette","year":"2018","journal-title":"Cancer Cell"},{"key":"key20200713162310_b4-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1152\/physrev.00005.2017","article-title":"Notch signaling in development, tissue homeostasis, and disease","volume":"97","author":"Siebel","year":"2017","journal-title":"Physiol Rev"},{"key":"key20200713162310_b5-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-018-0858-8","article-title":"Human blood vessel organoids as a model of diabetic vasculopathy","volume":"565","author":"Wimmer","year":"2019","journal-title":"Nature"},{"key":"key20200713162310_b6-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc3035","article-title":"Notch signalling in solid tumours: A little bit of everything but not all the time","volume":"11","author":"Ranganathan","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b7-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccr.2014.02.018","article-title":"From fly wings to targeted cancer therapies: A centennial for notch signaling","volume":"25","author":"Ntziachristos","year":"2014","journal-title":"Cancer Cell"},{"key":"key20200713162310_b8-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","article-title":"The varied roles of Notch in cancer","volume":"12","author":"Aster","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"key20200713162310_b9-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.145","article-title":"Notch as a tumour suppressor","volume":"17","author":"Nowell","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b10-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pharmthera.2013.02.003","article-title":"Notch inhibitors for cancer treatment","volume":"139","author":"Espinoza","year":"2013","journal-title":"Pharmacol Ther"},{"key":"key20200713162310_b11-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update","volume":"12","author":"Takebe","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713162310_b12-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: An emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"key20200713162310_b13-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1038\/onc.2008.229","article-title":"The many facets of Notch ligands","volume":"27","author":"D'Souza","year":"2008","journal-title":"Oncogene"},{"key":"key20200713162310_b14-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2159-8290.CD-14-0650","article-title":"NOTCH decoys that selectively block DLL\/NOTCH or JAG\/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth","volume":"5","author":"Kangsamaksin","year":"2015","journal-title":"Cancer Discov"},{"key":"key20200713162310_b15-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.devcel.2016.12.013","article-title":"Deciphering the Fringe-mediated Notch code: Identification of activating and inhibiting sites allowing discrimination between ligands","volume":"40","author":"Kakuda","year":"2017","journal-title":"Dev Cell"},{"key":"key20200713162310_b16-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2018.01.002","article-title":"Dynamic ligand discrimination in the Notch signaling pathway","volume":"172","author":"Nandagopal","year":"2018","journal-title":"Cell"},{"key":"key20200713162310_b17-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ydbio.2017.09.032","article-title":"Do as I say, Not(ch) as I do: Lateral control of cell fate","volume":"447","author":"Sj\u00f6qvist","year":"2019","journal-title":"Dev Biol"},{"key":"key20200713162310_b18-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-018-0068-5","article-title":"The emerging role of ADAM metalloproteinases in immunity","volume":"18","author":"Lambrecht","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"key20200713162310_b19-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-018-0813-8","article-title":"Structural basis of Notch recognition by human \u03b3-secretase","volume":"565","author":"Yang","year":"2019","journal-title":"Nature"},{"key":"key20200713162310_b20-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical Notch signaling pathway: Unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"key":"key20200713162310_b21-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nm1524","article-title":"Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia","volume":"13","author":"Vilimas","year":"2007","journal-title":"Nat Med"},{"key":"key20200713162310_b22-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nsmb.3013","article-title":"Notch is a direct negative regulator of the DNA-damage response","volume":"22","author":"Vermezovic","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"key20200713162310_b23-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature24998","article-title":"A non-canonical Notch complex regulates adherens junctions and vascular barrier function","volume":"552","author":"Polacheck","year":"2017","journal-title":"Nature"},{"key":"key20200713162310_b24-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to \u03b3-secretase inhibitors","volume":"204","author":"O'Neil","year":"2007","journal-title":"J Exp Med"},{"key":"key20200713162310_b25-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc3700","article-title":"Roles of F-box proteins in cancer","volume":"14","author":"Wang","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b26-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41392-018-0028-3","article-title":"USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia","volume":"3","author":"Shan","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"key20200713162310_b27-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"15515","DOI":"10.1038\/s41598-018-33920-y","article-title":"Src kinase phosphorylates Notch1 to inhibit MAML binding","volume":"8","author":"LaFoya","year":"2018","journal-title":"Sci Rep"},{"key":"key20200713162310_b28-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"8782","DOI":"10.1038\/srep08782","article-title":"AKT and 143-3 regulate Notch4 nuclear localization","volume":"5","author":"Ramakrishnan","year":"2015","journal-title":"Sci Rep"},{"key":"key20200713162310_b29-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1242\/jcs.068965","article-title":"Trp53 regulates Notch 4 signaling through Mdm2","volume":"124","author":"Sun","year":"2011","journal-title":"J Cell Sci"},{"key":"key20200713162310_b30-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"23196","DOI":"10.1074\/jbc.M302827200","article-title":"Mammalian Numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain","volume":"278","author":"McGill","year":"2003","journal-title":"J Biol Chem"},{"key":"key20200713162310_b31-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1042\/BJ20121249","article-title":"Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signalling pathway","volume":"450","author":"Pettersson","year":"2013","journal-title":"Biochem J"},{"key":"key20200713162310_b32-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-017-02363-w","article-title":"Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation","volume":"8","author":"Bhardwaj","year":"2017","journal-title":"Nat Commun"},{"key":"key20200713162310_b33-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"e12172","DOI":"10.1371\/journal.pone.0012172","article-title":"Delta-like 4 differentially regulates murine CD4 T cell expansion via BMI1","volume":"5","author":"Schaller","year":"2010","journal-title":"PLoS One"},{"key":"key20200713162310_b34-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1242\/dev.107714","article-title":"Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch","volume":"142","author":"L\u00f3pez-Arribillaga","year":"2015","journal-title":"Development"},{"key":"key20200713162310_b35-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1128\/MCB.21.17.5925-5934.2001","article-title":"Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): Implication for cell cycle disruption in transformation by Notch(ic)","volume":"21","author":"Ronchini","year":"2001","journal-title":"Mol Cell Biol"},{"key":"key20200713162310_b36-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/cpt.335","article-title":"An accessible pharmacodynamic transcriptional biomarker for Notch target engagement","volume":"99","author":"Tanis","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"key20200713162310_b37-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1172\/JCI92981","article-title":"The NOTCH1\/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model","volume":"128","author":"Garc\u00eda-Peydr\u00f3","year":"2018","journal-title":"J Clin Invest"},{"key":"key20200713162310_b38-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/emboj\/20.13.3427","article-title":"Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation","volume":"20","author":"Rangarajan","year":"2001","journal-title":"EMBO J"},{"key":"key20200713162310_b39-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/ncb3228","article-title":"Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation","volume":"17","author":"Procopio","year":"2015","journal-title":"Nat Cell Biol"},{"key":"key20200713162310_b40-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1128\/MCB.18.12.7423","article-title":"Delta-1 activation of Notch-1 signaling results in HES-1 transactivation","volume":"18","author":"Jarriault","year":"1998","journal-title":"Mol Cell Biol"},{"key":"key20200713162310_b41-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","article-title":"Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer","volume":"545","author":"Lim","year":"2017","journal-title":"Nature"},{"key":"key20200713162310_b42-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-13-0830","article-title":"Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma","volume":"4","author":"Stoeck","year":"2014","journal-title":"Cancer Discov"},{"key":"key20200713162310_b43-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1006\/bbrc.2000.3354","article-title":"Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes","volume":"275","author":"Maier","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"key20200713162310_b44-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1101\/gad.1450406","article-title":"c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia\/lymphoma","volume":"20","author":"Weng","year":"2006","journal-title":"Genes Dev"},{"key":"key20200713162310_b45-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/leu.2016.106","article-title":"\u03b2-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1","volume":"30","author":"Gekas","year":"2016","journal-title":"Leukemia"},{"key":"key20200713162310_b46-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fonc.2019.00198","article-title":"Histone modifications drive aberrant Notch3 expression\/activity and growth in T-ALL","volume":"9","author":"Tottone","year":"2019","journal-title":"Front Oncol"},{"key":"key20200713162310_b47-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.bbrc.2004.07.157","article-title":"Direct regulation of the Nrarp gene promoter by the Notch signaling pathway","volume":"322","author":"Pirot","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"key20200713162310_b48-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1128\/MCB.01408-13","article-title":"Notch-Nrf2 axis: Regulation of Nrf2 gene expression and cytoprotection by Notch signaling","volume":"34","author":"Wakabayashi","year":"2014","journal-title":"Mol Cell Biol"},{"key":"key20200713162310_b49-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1242\/dev.070763","article-title":"Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells","volume":"139","author":"VanDussen","year":"2012","journal-title":"Development"},{"key":"key20200713162310_b50-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature10279","article-title":"A critical role for TCF-1 in T-lineage specification and differentiation","volume":"476","author":"Weber","year":"2011","journal-title":"Nature"},{"key":"key20200713162310_b51-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"20060","DOI":"10.1073\/pnas.1110230108","article-title":"T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling","volume":"108","author":"Germar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713162310_b52-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ceb.2017.12.008","article-title":"Notch after cleavage","volume":"51","author":"Bray","year":"2018","journal-title":"Curr Opin Cell Biol"},{"key":"key20200713162310_b53-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1073\/pnas.1717125115","article-title":"Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713162310_b54-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"key20200713162310_b55-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lympho-blastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"key20200713162310_b56-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/sj.leu.2404258","article-title":"CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors","volume":"20","author":"Palomero","year":"2006","journal-title":"Leukemia"},{"key":"key20200713162310_b57-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/s41375-018-0127-8","article-title":"Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia","volume":"32","author":"Bie De","year":"2018","journal-title":"Leukemia"},{"key":"key20200713162310_b58-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"key20200713162310_b59-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b60-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2017.251","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"32","author":"Karube","year":"2018","journal-title":"Leukemia"},{"key":"key20200713162310_b61-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"e0212813","DOI":"10.1371\/journal.pone.0212813","article-title":"Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"14","author":"Gonz\u00e1lez-Rinc\u00f3n","year":"2019","journal-title":"PLoS One"},{"key":"key20200713162310_b62-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"key20200713162310_b63-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/nm.2580","article-title":"Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer","volume":"17","author":"Robinson","year":"2011","journal-title":"Nat Med"},{"key":"key20200713162310_b64-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-14-1348","article-title":"PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a \u03b3-secretase inhibitor","volume":"21","author":"Wang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b65-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"key":"key20200713162310_b66-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"22293","DOI":"10.1073\/pnas.0907781106","article-title":"Alterations of the Notch pathway in lung cancer","volume":"106","author":"Westhoff","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713162310_b67-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"17761","DOI":"10.1073\/pnas.1114669108","article-title":"Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma","volume":"108","author":"Wang","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713162310_b68-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science"},{"key":"key20200713162310_b69-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"key20200713162310_b70-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature13176","article-title":"Identification of genomic alterations in oesophageal squamous cell cancer","volume":"509","author":"Song","year":"2014","journal-title":"Nature"},{"key":"key20200713162310_b71-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1126\/science.aau3879","article-title":"Somatic mutant clones colonize the human esophagus with age","volume":"362","author":"Martincorena","year":"2018","journal-title":"Science"},{"key":"key20200713162310_b72-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"key20200713162310_b73-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ccell.2016.02.012","article-title":"Protein kinase C\u03b9 drives a NOTCH3-dependent stem-like phenotype in mutant KRAS lung adenocarcinoma","volume":"29","author":"Ali","year":"2016","journal-title":"Cancer Cell"},{"key":"key20200713162310_b74-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1074\/jbc.M116.745208","article-title":"Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer","volume":"292","author":"Bhagat","year":"2017","journal-title":"J Biol Chem"},{"key":"key20200713162310_b75-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41467-019-09470-w","article-title":"A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma","volume":"10","author":"van Groningen","year":"2019","journal-title":"Nat Commun"},{"key":"key20200713162310_b76-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1158\/0008-5472.CAN-07-6145","article-title":"EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma","volume":"68","author":"Ban","year":"2008","journal-title":"Cancer Res"},{"key":"key20200713162310_b77-ijmm-45-02-0279","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert","year":"2019","journal-title":"Sci Signal"},{"key":"key20200713162310_b78-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.fob.2015.08.007","article-title":"Activation of Notch3 promotes pulmonary arterial smooth muscle cells proliferation via Hes1\/p27Kip1 signaling pathway","volume":"5","author":"Song","year":"2015","journal-title":"FEBS Open Bio"},{"key":"key20200713162310_b79-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ccr.2012.06.014","article-title":"Therapeutic effect of \u03b3-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK","volume":"22","author":"Maraver","year":"2012","journal-title":"Cancer Cell"},{"key":"key20200713162310_b80-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat Med"},{"key":"key20200713162310_b81-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/stem.1426","article-title":"Hes1 desynchronizes differentiation of pluripotent cells by modulating STAT3 activity","volume":"31","author":"Zhou","year":"2013","journal-title":"Stem Cells"},{"key":"key20200713162310_b82-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"e0144322","DOI":"10.1371\/journal.pone.0144322","article-title":"Hes1 increases the invasion ability of colorectal cancer cells via the STAT3-MMP14 pathway","volume":"10","author":"Weng","year":"2015","journal-title":"PLoS One"},{"key":"key20200713162310_b83-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1038\/onc.2012.517","article-title":"Non-canonical Notch signaling activates IL-6\/JAK\/STAT signaling in breast tumor cells and is controlled by p53 and IKK\u03b1\/IKK\u03b2","volume":"32","author":"Jin","year":"2013","journal-title":"Oncogene"},{"key":"key20200713162310_b84-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1158\/1078-0432.CCR-10-1624","article-title":"The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: A potential mechanism of therapeutic resistance","volume":"16","author":"Schreck","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b85-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/0008-5472.CAN-15-1722","article-title":"Notch4 signaling induces a mesenchymal-epithelial-like transition in melanoma cells to suppress malignant behaviors","volume":"76","author":"Bonyadi Rad","year":"2016","journal-title":"Cancer Res"},{"key":"key20200713162310_b86-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/cdd.2017.162","article-title":"IL6 blockade potentiates the anti-tumor effects of \u03b3-secretase inhibitors in Notch3-expressing breast cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Death Differ"},{"key":"key20200713162310_b87-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"15792","DOI":"10.1073\/pnas.1002827107","article-title":"Notch signaling specifies prosensory domains via lateral induction in the developing mammalian inner ear","volume":"107","author":"Hartman","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713162310_b88-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1242\/dev.108100","article-title":"Ligand-dependent Notch signaling strength orchestrates lateral induction and lateral inhibition in the developing inner ear","volume":"141","author":"Petrovic","year":"2014","journal-title":"Development"},{"key":"key20200713162310_b89-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/0008-5472.CAN-13-1259","article-title":"Activation of the NOTCH pathway in head and neck cancer","volume":"74","author":"Sun","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713162310_b90-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","article-title":"Immunological hallmarks of stromal cells in the tumour microenvironment","volume":"15","author":"Turley","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"key20200713162310_b91-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713162310_b92-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.trecan.2018.10.004","article-title":"Microvascular mural cells in cancer","volume":"4","author":"\u00d6stman","year":"2018","journal-title":"Trends Cancer"},{"key":"key20200713162310_b93-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","article-title":"Phenotype molding of stromal cells in the lung tumor microenvironment","volume":"24","author":"Lambrechts","year":"2018","journal-title":"Nat Med"},{"key":"key20200713162310_b94-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","article-title":"Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing","volume":"9","author":"Bartoschek","year":"2018","journal-title":"Nat Commun"},{"key":"key20200713162310_b95-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b96-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","article-title":"The lung microenvironment: An important regulator of tumour growth and metastasis","volume":"19","author":"Altorki","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b97-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10555-019-09793-6","article-title":"Exosomes, metastases, and the miracle of cancer stem cell markers","volume":"38","author":"Wang","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"key20200713162310_b98-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)","volume":"51","author":"Katoh","year":"2017","journal-title":"Int J Oncol"},{"key":"key20200713162310_b99-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1172\/JCI72589","article-title":"Multifocal epithelial tumors and field cancerization: Stroma as a primary determinant","volume":"124","author":"Dotto","year":"2014","journal-title":"J Clin Invest"},{"key":"key20200713162310_b100-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: The mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713162310_b101-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"key20200713162310_b102-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713162310_b103-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1128\/JVI.66.4.2594-2599.1992","article-title":"Mouse mammary tumor gene int-3: A member of the Notch gene family transforms mammary epithelial cells","volume":"66","author":"Robbins","year":"1992","journal-title":"J Virol"},{"key":"key20200713162310_b104-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/320628a0","article-title":"Concerted activation of two potential proto-oncogenes in carcinomas induced by mouse mammary tumour virus","volume":"320","author":"Peters","year":"1986","journal-title":"Nature"},{"key":"key20200713162310_b105-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1073\/pnas.90.2.740","article-title":"Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2\/Fgf-3 and hst\/Fgf-4","volume":"90","author":"Shackleford","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713162310_b106-ijmm-45-02-0279","first-page":"1269","article-title":"WNT and FGF gene clusters (review)","volume":"21","author":"Katoh","year":"2002","journal-title":"Int J Oncol"},{"key":"key20200713162310_b107-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"10093","DOI":"10.1128\/JVI.79.15.10093-10096.2005","article-title":"A new common integration site, Int7, for the mouse mammary tumor virus in mouse mammary tumors identifies a gene whose product has furin-like and thrombospondin-like sequences","volume":"79","author":"Lowther","year":"2005","journal-title":"J Virol"},{"key":"key20200713162310_b108-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/ng2034","article-title":"MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer","volume":"39","author":"Theodorou","year":"2007","journal-title":"Nat Genet"},{"key":"key20200713162310_b109-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"key20200713162310_b110-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41416-018-0118-6","article-title":"Targeting LGR5 in colorectal cancer: Therapeutic gold or too plastic","volume":"118","author":"Morgan","year":"2018","journal-title":"Br J Cancer"},{"key":"key20200713162310_b111-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1242\/dev.02644","article-title":"Jagged 1 is a beta-catenin target gene required for ectopic hair follicle formation in adult epidermis","volume":"133","author":"Estrach","year":"2006","journal-title":"Development"},{"key":"key20200713162310_b112-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.stemcr.2019.04.007","article-title":"WNT\/NOTCH pathway is essential for the maintenance and expansion of human MGE progenitors","volume":"12","author":"Ma","year":"2019","journal-title":"Stem Cell Reports"},{"key":"key20200713162310_b113-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nm.2667","article-title":"Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease","volume":"18","author":"Boulter","year":"2012","journal-title":"Nat Med"},{"key":"key20200713162310_b114-ijmm-45-02-0279","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/0008-5472.CAN-18-0451","article-title":"Transcription factor PROX1 suppresses Notch pathway activation via the nucleosome remod-eling and deacetylase complex in colorectal cancer stem-like cells","volume":"78","author":"H\u00f6gstr\u00f6m","year":"2018","journal-title":"Cancer Res"},{"key":"key20200713162310_b115-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.devcel.2008.12.009","article-title":"Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis","volume":"16","author":"Phng","year":"2009","journal-title":"Dev Cell"},{"key":"key20200713162310_b116-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1038\/onc.2016.58","article-title":"Olfactomedin 4 deletion induces colon adenocarcinoma in ApcMin\/+ mice","volume":"35","author":"Liu","year":"2016","journal-title":"Oncogene"},{"key":"key20200713162310_b117-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","article-title":"Mechanisms governing metastatic dormancy and reactivation","volume":"155","author":"Giancotti","year":"2013","journal-title":"Cell"},{"key":"key20200713162310_b118-ijmm-45-02-0279","first-page":"713","article-title":"Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT\/\u03b2-catenin signaling activation (Review)","volume":"42","author":"Katoh","year":"2018","journal-title":"Int J Mol Med"},{"key":"key20200713162310_b119-ijmm-45-02-0279","first-page":"4736","article-title":"The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells","volume":"62","author":"Dimri","year":"2002","journal-title":"Cancer Res"},{"key":"key20200713162310_b120-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"e1006682","DOI":"10.1371\/journal.pgen.1006682","article-title":"Wnt\/Tcf1 pathway restricts embryonic stem cell cycle through activation of the Ink4\/Arf locus","volume":"13","author":"De Jaime-Soguero","year":"2017","journal-title":"PLoS Genet"},{"key":"key20200713162310_b121-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1158\/0008-5472.CAN-15-3198","article-title":"NOTCH signaling regulates asymmetric cell fate of fast- and slow-cycling colon cancer-initiating cells","volume":"76","author":"Srinivasan","year":"2016","journal-title":"Cancer Res"},{"key":"key20200713162310_b122-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.scr.2014.08.002","article-title":"Tripartite interactions between Wnt signaling, Notch and Myb for stem\/progenitor cell functions during intestinal tumorigenesis","volume":"13","author":"Germann","year":"2014","journal-title":"Stem Cell Res"},{"key":"key20200713162310_b123-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41598-018-37301-3","article-title":"Lineage tracing of Notch1-expressing cells in intestinal tumours reveals a distinct population of cancer stem cells","volume":"9","author":"Mourao","year":"2019","journal-title":"Sci Rep"},{"key":"key20200713162310_b124-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b125-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b126-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.bbagen.2019.04.017","article-title":"Tumor-induced neoangiogenesis and receptor tyrosine kinases-Mechanisms and strategies for acquired resistance","volume":"1863","author":"Yunus","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"key20200713162310_b127-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis","volume":"146","author":"Potente","year":"2011","journal-title":"Cell"},{"key":"key20200713162310_b128-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20200713162310_b129-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2217\/fon.11.20","article-title":"Notch regulation of tumor angiogenesis","volume":"7","author":"Bridges","year":"2011","journal-title":"Future Oncol"},{"key":"key20200713162310_b130-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20200713162310_b131-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccell.2017.01.007","article-title":"Endothelial Notch1 activity facilitates metastasis","volume":"31","author":"Wieland","year":"2017","journal-title":"Cancer Cell"},{"key":"key20200713162310_b132-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/0008-5472.CAN-18-1752","article-title":"Hepatic endothelial Notch activation protects against liver metastasis by regulating endothelial-tumor cell adhesion independent of angiocrine signaling","volume":"79","author":"Wohlfeil","year":"2019","journal-title":"Cancer Res"},{"key":"key20200713162310_b133-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nri3445","article-title":"Regulation of innate and adaptive immunity by Notch","volume":"13","author":"Radtke","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"key20200713162310_b134-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2013-08-355818","article-title":"Notch signaling: Switching an oncogene to a tumor suppressor","volume":"123","author":"Lobry","year":"2014","journal-title":"Blood"},{"key":"key20200713162310_b135-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.it.2015.10.007","article-title":"Notch in T cell differentiation: all things considered","volume":"36","author":"Amsen","year":"2015","journal-title":"Trends Immunol"},{"key":"key20200713162310_b136-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/ni.3288","article-title":"Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling","volume":"16","author":"Charbonnier","year":"2015","journal-title":"Nat Immunol"},{"key":"key20200713162310_b137-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-10-0269","article-title":"Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses","volume":"70","author":"Wang","year":"2010","journal-title":"Cancer Res"},{"key":"key20200713162310_b138-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-017-4394-2","article-title":"Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients","volume":"166","author":"Liu","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"key20200713162310_b139-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/stem.2485","article-title":"TLR3 or TLR4 activation enhances mesenchymal stromal cell-mediated Treg induction via Notch signaling","volume":"35","author":"Rashedi","year":"2017","journal-title":"Stem Cells"},{"key":"key20200713162310_b140-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13287-015-0021-5","article-title":"Jagged-1 is required for the expansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells","volume":"6","author":"Cahill","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"key20200713162310_b141-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.immuni.2006.09.008","article-title":"Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through Notch signaling","volume":"25","author":"Kared","year":"2006","journal-title":"Immunity"},{"key":"key20200713162310_b142-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41385-018-0052-1","article-title":"Notch ligand Delta-like 4 induces epigenetic regulation of Treg cell differentiation and function in viral infection","volume":"11","author":"Ting","year":"2018","journal-title":"Mucosal Immunol"},{"key":"key20200713162310_b143-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","article-title":"Lineage tracking reveals dynamic relationships of T cells in colorectal cancer","volume":"564","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"key20200713162310_b144-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.devcel.2005.09.010","article-title":"Hypoxia requires Notch signaling to maintain the undifferentiated cell state","volume":"9","author":"Gustafsson","year":"2005","journal-title":"Dev Cell"},{"key":"key20200713162310_b145-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"key20200713162310_b146-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1189\/jlb.1VMR1216-505R","article-title":"The mazy case of Notch and immunoregulatory cells","volume":"102","author":"Grazioli","year":"2017","journal-title":"J Leukoc Biol"},{"key":"key20200713162310_b147-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1042\/CS20180845","article-title":"Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers","volume":"133","author":"Katoh","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"key20200713162310_b148-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0664-4","article-title":"Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-\u03b21","volume":"37","author":"Yang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"key20200713162310_b149-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ijc.31115","article-title":"\u03b3-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma","volume":"142","author":"Mao","year":"2018","journal-title":"Int J Cancer"},{"issue":"15 Suppl","key":"key20200713162310_b150-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"S2515","DOI":"10.1200\/JCO.2018.36.15_suppl.2515","article-title":"A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors","volume":"36","author":"El-Khoueiry","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b151-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/annonc\/mdy244","article-title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","volume":"29","author":"Massard","year":"2018","journal-title":"Ann Oncol"},{"key":"key20200713162310_b152-ijmm-45-02-0279","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6246","article-title":"Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition","volume":"11","author":"Habets","year":"2019","journal-title":"Sci Transl Med"},{"key":"key20200713162310_b153-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","article-title":"A phase I, dose-finding study in patients with advanced solid malignancies of the oral \u03b3-secretase inhibitor PF-03084014","volume":"21","author":"Messersmith","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b154-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/JCO.2016.71.1994","article-title":"Clinical activity of the \u03b3-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis)","volume":"35","author":"Kummar","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b155-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secre-tase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","volume":"30","author":"Tolcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b156-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ejca.2012.02.056","article-title":"A phase II study of RO4929097 in metastatic colorectal cancer","volume":"48","author":"Strosberg","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20200713162310_b157-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature19328","article-title":"HER2 expression identifies dynamic functional states within circulating breast cancer cells","volume":"537","author":"Jordan","year":"2016","journal-title":"Nature"},{"key":"key20200713162310_b158-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41389-018-0051-9","article-title":"NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest","volume":"7","author":"Diluvio","year":"2018","journal-title":"Oncogenesis"},{"key":"key20200713162310_b159-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4161\/cbt.25332","article-title":"Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT\/\u03b2-catenin","volume":"14","author":"Yao","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"key20200713162310_b160-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"6295","DOI":"10.1158\/1078-0432.CCR-14-1373","article-title":"A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors","volume":"20","author":"Smith","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b161-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-14-2797","article-title":"A phase I first-in-human study of enoticumab (REGN421), a fully human Delta-like ligand 4 (DLL4) monoclonal antibody, in patients with advanced solid tumors","volume":"21","author":"Chiorean","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"15 Suppl","key":"key20200713162310_b162-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"S3024","DOI":"10.1200\/jco.2015.33.15_suppl.3024","article-title":"Phase I study of MEDI0639 in patients with advanced solid tumors","volume":"33","author":"Falchook","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b163-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Ann Oncol"},{"key":"key20200713162310_b164-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1158\/1078-0432.CCR-14-2808","article-title":"Targeting Notch signaling with a Notch2\/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency","volume":"21","author":"Yen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b165-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s10637-018-0714-6","article-title":"A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors","volume":"37","author":"Smith","year":"2019","journal-title":"Invest New Drugs"},{"key":"key20200713162310_b166-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713162310_b167-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-Drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"key":"key20200713162310_b168-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: Pursuit of the 'high-hanging fruit'","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713162310_b169-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"key20200713162310_b170-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"key20200713162310_b171-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"key20200713162310_b172-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"S8507","DOI":"10.1200\/JCO.2018.36.15_suppl.8507","article-title":"Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, \u2265 3rd line small cell lung cancer: Results from the phase 2 TRINITY study","volume":"36","author":"Carbone","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b173-ijmm-45-02-0279","article-title":"A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors","author":"Rosen","year":"2019","journal-title":"Invest New Drugs"},{"issue":"15 Suppl","key":"key20200713162310_b174-ijmm-45-02-0279","doi-asserted-by":"crossref","first-page":"TPS8577","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8577","article-title":"Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC)","volume":"37","author":"Smit","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b175-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/1535-7163.MCT-17-0800","article-title":"ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting DLL4 and VEGF, demonstrates superior efficacy and favorable safety profiles in preclinical models","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"key20200713162310_b176-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10637-018-0665-y","article-title":"A first-in-human phase 1a study of the bispecific anti-DLL4\/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors","volume":"37","author":"Jimeno","year":"2019","journal-title":"Invest New Drugs"},{"key":"key20200713162310_b177-ijmm-45-02-0279","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0339","article-title":"Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency","volume":"9","author":"Hu","year":"2017","journal-title":"Sci Transl Med"},{"key":"key20200713162310_b178-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-18-2732","article-title":"EGFR\/Notch antagonists enhance the response to inhibitors of the PI3K-Akt pathway by decreasing tumor-initiating cell frequency","volume":"25","author":"Fu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15 Suppl","key":"key20200713162310_b179-ijmm-45-02-0279","doi-asserted-by":"crossref","first-page":"TPS8576","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8576","article-title":"Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed\/refractory small cell lung cancer (SCLC)","volume":"37","author":"Byers","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b180-ijmm-45-02-0279","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"key20200713162310_b181-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 12 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20200713162310_b182-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"key20200713162310_b183-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"key20200713162310_b184-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"key20200713162310_b185-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: An open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20200713162310_b186-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"key20200713162310_b187-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: A phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20200713162310_b188-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20200713162310_b189-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/neuonc\/noy091","article-title":"Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: Results from an international phase I multicenter trial","volume":"21","author":"Lassman","year":"2019","journal-title":"Neuro Oncol"},{"key":"key20200713162310_b190-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b191-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"key20200713162310_b192-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecanhziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"key20200713162310_b193-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"key20200713162310_b194-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-18-0624","article-title":"MEN1309\/OBT076, a first-in-class antibody-drug conjugate targeting CD205 in solid tumors","volume":"18","author":"Merlino","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"15 Suppl","key":"key20200713162310_b195-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"S2509","DOI":"10.1200\/JCO.2019.37.15_suppl.2509","article-title":"Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma","volume":"37","author":"Zhan","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b196-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody-drug conjugates","volume":"78","author":"Garc\u00eda-Alonso","year":"2018","journal-title":"Cancer Res"},{"key":"key20200713162310_b197-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713162310_b198-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"key20200713162310_b199-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"key20200713162310_b200-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.suc.2019.02.005","article-title":"Next-generation sequencing in the management of gastric and esophageal cancers","volume":"99","author":"Rubinstein","year":"2019","journal-title":"Surg Clin North Am"},{"key":"key20200713162310_b201-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"key20200713162310_b202-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b203-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b204-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ijc.31878","article-title":"Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis","volume":"144","author":"Buchhalter","year":"2019","journal-title":"Int J Cancer"},{"key":"key20200713162310_b205-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrd.2017.232","article-title":"Automating drug discovery","volume":"17","author":"Schneider","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"key20200713162310_b206-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200713162310_b207-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/annonc\/mdx781","article-title":"Watson for oncology and breast cancer treatment recommendations: Agreement with an expert multidisciplinary tumor board","volume":"29","author":"Somashekhar","year":"2018","journal-title":"Ann Oncol"},{"key":"key20200713162310_b208-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12859-019-2971-6","article-title":"The MultiOmics explainer: Explaining omics results in the context of a pathway\/genome database","volume":"20","author":"Paley","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"key20200713162310_b209-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"24454","DOI":"10.1038\/srep24454","article-title":"Computer-aided diagnosis with deep learning architecture: Applications to breast lesions in US images and pulmonary nodules in CT scans","volume":"6","author":"Cheng","year":"2016","journal-title":"Sci Rep"},{"key":"key20200713162310_b210-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature21056","article-title":"Dermatologist-level classification of skin cancer with deep neural networks","volume":"542","author":"Esteva","year":"2017","journal-title":"Nature"},{"key":"key20200713162310_b211-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-019-0447-x","article-title":"End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography","volume":"25","author":"Ardila","year":"2019","journal-title":"Nat Med"},{"key":"key20200713162310_b212-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ebiom.2019.04.055","article-title":"Skin cancer detection by deep learning and sound analysis algorithms: A prospective clinical study of an elementary dermoscope","volume":"43","author":"Dascalu","year":"2019","journal-title":"EBioMedicine"},{"key":"key20200713162310_b213-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"357","DOI":"10.7326\/M18-0249","article-title":"Real-time use of artificial intelligence in identification of diminutive polyps during colonoscopy: A prospective study","volume":"169","author":"Mori","year":"2018","journal-title":"Ann Intern Med"},{"key":"key20200713162310_b214-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1158\/1078-0432.CCR-18-1115","article-title":"Deep learning to distinguish recalled but benign mammography images in breast cancer screening","volume":"24","author":"Aboutalib","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b215-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","article-title":"Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning","volume":"24","author":"Coudray","year":"2018","journal-title":"Nat Med"},{"key":"key20200713162310_b216-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41591-019-0462-y","article-title":"Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer","volume":"25","author":"Kather","year":"2019","journal-title":"Nat Med"},{"key":"key20200713162310_b217-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/s41591-019-0508-1","article-title":"Clinical-grade computational pathology using weakly supervised deep learning on whole slide images","volume":"25","author":"Campanella","year":"2019","journal-title":"Nat Med"},{"key":"key20200713162310_b218-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2019.06.012","article-title":"Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images","volume":"118","author":"Hekler","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20200713162310_b219-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: The convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med"},{"key":"key20200713162310_b220-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ccell.2017.11.002","article-title":"Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy","volume":"32","author":"Zheng","year":"2017","journal-title":"Cancer Cell"},{"key":"key20200713162310_b221-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"e12480","DOI":"10.1111\/cpr.12480","article-title":"A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo","volume":"51","author":"Li","year":"2018","journal-title":"Cell Prolif"},{"issue":"Suppl 5","key":"key20200713162310_b222-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"v122","DOI":"10.1093\/annonc\/mdx367.044","article-title":"411P-Pharmacological activity of CB-103-an oral pan-NOTCH inhibitor with a novel mode of action","volume":"28","author":"Weber","year":"2017","journal-title":"Ann Oncol"},{"key":"key20200713162310_b223-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature08543","article-title":"Direct inhibition of the NOTCH transcription factor complex","volume":"462","author":"Moellering","year":"2009","journal-title":"Nature"},{"key":"key20200713162310_b224-ijmm-45-02-0279","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9732","article-title":"An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma","volume":"11","author":"Sano","year":"2019","journal-title":"Sci Transl Med"},{"key":"key20200713162310_b225-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat Med"},{"key":"key20200713162310_b226-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/1878-0261.12520","article-title":"Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma","volume":"13","author":"Tao","year":"2019","journal-title":"Mol Oncol"},{"key":"key20200713162310_b227-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1158\/0008-5472.CAN-16-0180","article-title":"Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors","volume":"76","author":"Sommer","year":"2016","journal-title":"Cancer Res"},{"issue":"13 Suppl","key":"key20200713162310_b228-ijmm-45-02-0279","doi-asserted-by":"crossref","first-page":"S4835","DOI":"10.1158\/1538-7445.AM2019-4835","article-title":"LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions","volume":"79","author":"Surguladze","year":"2019","journal-title":"Cancer Res"},{"issue":"14 Suppl","key":"key20200713162310_b229-ijmm-45-02-0279","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1158\/1538-7445.AM2016-574","article-title":"AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status","volume":"76","author":"Rudra-Ganguly","year":"2016","journal-title":"Cancer Res"},{"key":"key20200713162310_b230-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/1535-7163.MCT-17-0795","article-title":"MI130004, a novel antibody-drug conjugate combining trastuzumab with a molecule of marine origin, shows outstanding in iivo activity against HER2-expressing tumors","volume":"17","author":"Avil\u00e9s","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"key20200713162310_b231-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-19-0452","article-title":"U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of colorectal cancer","volume":"18","author":"Koganemaru","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"key20200713162310_b232-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/1078-0432.CCR-17-3795","article-title":"Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors","volume":"24","author":"Abrams","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b233-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","article-title":"First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors","volume":"36","author":"Strickler","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15-Suppl","key":"key20200713162310_b234-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"S5565","DOI":"10.1200\/JCO.2018.36.15_suppl.5565","article-title":"PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study","volume":"36","author":"Sachdev","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b235-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-15-0468","article-title":"Preclinical efficacy and safety assessment of an antibody-drug conjugate targeting the c-RET proto-oncogene for breast carcinoma","volume":"21","author":"Nguyen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200713162310_b236-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40425-019-0525-0","article-title":"Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt\/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy","volume":"7","author":"Yao","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20200713162310_b237-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"key20200713162310_b238-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"key20200713162310_b239-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"key20200713162310_b240-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cllc.2016.09.002","article-title":"Phase 1\/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin\/etoposide in small-cell lung cancer patients with extensive-stage disease","volume":"18","author":"Socinski","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"key20200713162310_b241-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20200713162310_b242-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II trial of labetuzumab govitecan (anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20200713162310_b243-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","article-title":"Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci Rep"},{"key":"key20200713162310_b244-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/1535-7163.MCT-17-0813","article-title":"An anti-GDNF family receptor alpha 1 (GFRA1) antibody-drug conjugate for the treatment of hormone receptor-positive breast cancer","volume":"17","author":"Bhakta","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"key20200713162310_b245-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/cncr.31892","article-title":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma","volume":"125","author":"Ott","year":"2019","journal-title":"Cancer"},{"key":"key20200713162310_b246-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/1535-7163.MCT-16-0114","article-title":"LGR5-targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence","volume":"15","author":"Gong","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"key20200713162310_b247-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res"},{"key":"key20200713162310_b248-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1535-7163.MCT-16-0474","article-title":"Preclinical antitumor efficacy of BAY 1129980-a novel auristatin-based anti-C4.4A (LYPD3) antibody-drug conjugate for the treatment of non-small cell lung cancer","volume":"16","author":"Willuda","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"key20200713162310_b249-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20200713162310_b250-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/annonc\/mdy023","article-title":"Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","volume":"29","author":"Banerjee","year":"2018","journal-title":"Ann Oncol"},{"key":"key20200713162310_b251-ijmm-45-02-0279","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1158\/1535-7163.MCT-13-0896","article-title":"SGN-LIV1A: A novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer","volume":"13","author":"Sussman","year":"2014","journal-title":"Mol Cancer Ther"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T13:08:28Z","timestamp":1665148108000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2019.4418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":251,"URL":"https:\/\/doi.org\/10.3892\/ijmm.2019.4418","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]}}}